贝伐单抗的直接抗肿瘤活性：一种被忽视的机制？ - Suppr

Suppr

超能文献

Direct antitumor activity of bevacizumab: an overlooked mechanism?

作者信息

Wang Zhiyong, Li Jiaqi, Guo Jinjin, Wei Pei

机构信息

Department of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.

出版信息

Front Pharmacol. 2024 Apr 23;15:1394878. doi: 10.3389/fphar.2024.1394878. eCollection 2024.

DOI:10.3389/fphar.2024.1394878

PMID:38716237

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11075754/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e25/11075754/334cb82f8866/fphar-15-1394878-g001.jpg

相似文献

Direct antitumor activity of bevacizumab: an overlooked mechanism?贝伐单抗的直接抗肿瘤活性：一种被忽视的机制？

Front Pharmacol. 2024 Apr 23;15:1394878. doi: 10.3389/fphar.2024.1394878. eCollection 2024.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.使用基于抗体的疗法靶向血管内皮生长因子驱动的血管生成。

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de.

Monitoring antiangiogenesis of bevacizumab in zebrafish.监测贝伐单抗在斑马鱼中的抗血管生成作用。

Drug Des Devel Ther. 2018 Aug 6;12:2423-2430. doi: 10.2147/DDDT.S166330. eCollection 2018.

Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.伊沙匹隆（BMS-247550）联合贝伐单抗在多种体内肿瘤模型中的协同抗肿瘤活性。

Clin Cancer Res. 2008 Dec 15;14(24):8123-31. doi: 10.1158/1078-0432.CCR-08-0025.

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.贝伐珠单抗通过直接作用于肿瘤血管内皮细胞增强 T 白血病/淋巴瘤细胞的化疗效果。

Haematologica. 2011 Jun;96(6):927-31. doi: 10.3324/haematol.2010.037689. Epub 2011 Feb 17.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.贝伐单抗联合载有血管抑素的奥司他韦增强 U87 神经胶质瘤的抗血管生成作用并降低贝伐单抗诱导的侵袭

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.贝伐珠单抗提高了过继细胞因子诱导的杀伤细胞治疗非小细胞肺癌模型的抗肿瘤疗效。

Med Oncol. 2014 Jan;31(1):777. doi: 10.1007/s12032-013-0777-3. Epub 2013 Nov 24.

Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.贝伐珠单抗通过血管内皮生长因子 A/血管内皮生长因子受体 2 特异性蛋白 1 通路上调胸苷磷酸化酶增强氟尿嘧啶的抗肿瘤作用。

Cancer Sci. 2018 Oct;109(10):3294-3304. doi: 10.1111/cas.13779. Epub 2018 Sep 25.

Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.贝伐单抗联合卡培他滨和奥沙利铂在人结直肠癌异种移植模型中的抗肿瘤活性。

Oncol Rep. 2009 Aug;22(2):241-7.

Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study.贝伐珠单抗和阿柏西普在神经内分泌癌中的抗肿瘤活性：深入的临床前研究。

Neuroendocrinology. 2020;110(1-2):50-62. doi: 10.1159/000500591. Epub 2019 Apr 29.

引用本文的文献

In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy.深入了解与三级淋巴结构相关的肿瘤浸润性基质细胞及其在癌症免疫治疗中的潜在功能。

Exp Hematol Oncol. 2025 Aug 10;14(1):105. doi: 10.1186/s40164-025-00695-8.

Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance.高级别浆液性卵巢癌中的精准医学：靶向治疗与化疗耐药挑战

Int J Mol Sci. 2025 Mar 12;26(6):2545. doi: 10.3390/ijms26062545.

Immunomodulation on tumor immune microenvironment in acquired targeted therapy resistance and implication for immunotherapy resistance.获得性靶向治疗耐药中肿瘤免疫微环境的免疫调节及其对免疫治疗耐药的影响

Transl Oncol. 2025 Apr;54:102353. doi: 10.1016/j.tranon.2025.102353. Epub 2025 Mar 8.

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.肿瘤休眠与复发：理解癌症复发的分子机制

Mil Med Res. 2025 Feb 11;12(1):7. doi: 10.1186/s40779-025-00595-2.

本文引用的文献

Biology and therapeutic targeting of vascular endothelial growth factor A.血管内皮生长因子 A 的生物学和治疗靶向。

Nat Rev Mol Cell Biol. 2023 Nov;24(11):816-834. doi: 10.1038/s41580-023-00631-w. Epub 2023 Jul 25.

Tetrazolium-based colorimetric assays underestimat the direct antitumor effects of anti-VEGF agent bevacizumab.基于四唑盐的比色法检测低估了抗血管内皮生长因子药物贝伐珠单抗的直接抗肿瘤作用。

Toxicol In Vitro. 2023 Sep;91:105631. doi: 10.1016/j.tiv.2023.105631. Epub 2023 Jun 17.

The application and research progress of anti-angiogenesis therapy in tumor immunotherapy.抗血管生成治疗在肿瘤免疫治疗中的应用及研究进展。

Front Immunol. 2023 Jun 2;14:1198972. doi: 10.3389/fimmu.2023.1198972. eCollection 2023.

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance.卵巢癌微环境在抗血管生成耐药中的代谢重编程。

Acta Biochim Biophys Sin (Shanghai). 2023 Apr 6;55(6):938-947. doi: 10.3724/abbs.2023046.

Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance.靶向非小细胞肺癌中 BPTF 对 VEGF 的调控及其潜在的临床意义。

Eur J Med Res. 2022 Dec 19;27(1):299. doi: 10.1186/s40001-022-00935-1.

Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.肿瘤微环境中肿瘤血管生成和免疫抑制相互作用的调控：抗血管生成与免疫检查点阻断联合治疗的新视角。

Front Immunol. 2022 Nov 10;13:1035323. doi: 10.3389/fimmu.2022.1035323. eCollection 2022.

Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.雷莫芦单抗联合索拉非尼增强了索拉非尼对 HepG2 癌细胞的抑制作用。

Sci Rep. 2022 Oct 25;12(1):17889. doi: 10.1038/s41598-022-21582-w.

Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells.二甲双胍的抗癌作用：逆转贝伐单抗诱导的肿瘤缺氧，并降低人卵巢癌SKOV3细胞中癌症干细胞标志物CD44/CD117的表达。

Front Pharmacol. 2022 Aug 15;13:955984. doi: 10.3389/fphar.2022.955984. eCollection 2022.

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.尼拉帕利联合贝伐珠单抗维持治疗在一线含贝伐珠单抗化疗后晚期卵巢癌中的卵巢癌 II 期临床试验。

Gynecol Oncol. 2022 Aug;166(2):219-229. doi: 10.1016/j.ygyno.2022.05.020. Epub 2022 Jun 9.

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.安罗替尼下调由贝伐单抗引发的RGC32。

Front Oncol. 2022 May 18;12:875888. doi: 10.3389/fonc.2022.875888. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验